Replies to post #91831 on Biotech Values

[DewDiligence]

Ipilimumab MoA

This diagram from yesterday’s investor presentation elaborates on
#msg-47469758 and shows the other approaches to immuno-oncology
being employed by compounds in BMY’s pipeline. (All of these except
the CD137 antagonist came from the Medarex acquisition.)